Clinical characteristics of patient population
| Characteristics | Vigabatrin patients | Tiagabine patients | Control patients |
|---|---|---|---|
| Male/female | 20/12 | 8/4 | 7/7 |
| Age, mean years (range) | 43.1 (22–73) | 42.2 (26–70) | 40 (21–71) |
| Median duration of treatment, months (range) | 46.5 (27–78) vigabatrin | 29 (7–60) tiagabine | 0 |
| Median monthly seizure frequency, (range) | 3.6 (0–31) | 4.0 (1–30) | 3 (0–30) |
| Median number of prior AEDs, (range) | 6 (3–11) | 3 (2–4) | 3 (2–8) |
| Number of patients taking concomitant AEDs | |||
| carbamazepine | 19 | 4 | 6 |
| phenytoin | 9 | 3 | 7 |
| gabapentin | 4 | 1 | 2 |
| lamotrigine | 5 | 0 | 1 |
| phenobarbittal | 0 | 1 | 4 |
| primidone | 2 | 1 | 1 |
| topiramate | 1 | 1 | 3 |
| valproic acid | 4 | 0 | 3 |
| levetiracetam | 0 | 2 | 3 |
| Aetiology of seizures | |||
| idiopathic | 16 | 8 | 7 |
| symptomatic | 16 | 4 | 7 |